Edema Paru

01Pathophysiology

Pulmonary edema is the abnormal accumulation of fluid in the extravascular compartments of the lung, including the interstitium and alveolar spaces. To understand why this happens, you must recall the Starling equation, which governs fluid movement across the capillary membrane:

$$Q=K_f[(P_c-P_i)-\sigma ({\pi }_c-{\pi }_i)]Q\; =\; K\_f\; \backslash left[(P\_c\; -\; P\_i)\; -\; \backslash sigma(\backslash pi\_c\; -\; \backslash pi\_i)\backslash right]$$

where $QQ$ is the net fluid filtration, $K_{f}K\_f$ is the filtration coefficient (a measure of membrane permeability), $P_{c}P\_c$ is capillary hydrostatic pressure, $P_{i}P\_i$ is interstitial hydrostatic pressure, $\sigma \backslash sigma$ is the reflection coefficient, ${\pi }_c\backslash pi\_c$ is capillary oncotic pressure, and ${\pi }_i\backslash pi\_i$ is interstitial oncotic pressure.

Cardiogenic pulmonary edema arises when left-sided heart failure causes a rise in left atrial pressure, which transmits backward into the pulmonary veins and capillaries, elevating $P_{c}P\_c$. When the capillary hydrostatic pressure exceeds the oncotic pressure holding fluid in the vessel, fluid is driven out into the interstitium first (causing interstitial edema with Kerley B lines on imaging), and then into the alveoli themselves (causing alveolar flooding). This is why the patient develops crackles on auscultation: the opening of fluid-filled alveoli during inspiration creates the sound. The pink frothy sputum results from protein-rich fluid mixing with surfactant and small amounts of red blood cells in the alveoli. Orthopnea and PND occur because recumbency increases venous return, further elevating pulmonary capillary pressure in an already-failing left ventricle.

Non-cardiogenic pulmonary edema occurs through a fundamentally different mechanism. Here, the $K_{f}K\_f$ (membrane permeability) increases due to direct injury to the alveolar-capillary barrier. Inflammatory mediators (cytokines, neutrophil proteases, reactive oxygen species) damage the endothelial and epithelial layers, allowing protein-rich fluid to leak into the alveoli even at normal hydrostatic pressures. This is the hallmark of ARDS. Because the fluid is protein-rich and the barrier is structurally damaged, it does not respond to diuresis the way cardiogenic edema does.

A third and less common but highly testable category is neurogenic pulmonary edema, which occurs after acute CNS injury (subarachnoid hemorrhage, traumatic brain injury, seizures). The mechanism involves a catecholamine surge that causes sudden, intense pulmonary vasoconstriction and a transient spike in hydrostatic pressure, along with some degree of permeability injury.

02Classification and Clinical Manifestation

Clinical Staging of Cardiogenic Pulmonary Edema

03Diagnostic Workup

The chest X-ray is the best initial test when a patient presents with acute dyspnea and suspected pulmonary edema. In cardiogenic edema, look for the classic radiographic progression: vascular cephalization (redistribution of blood flow to the upper lobes), followed by interstitial markings (Kerley B lines, which are short horizontal lines at the lung periphery caused by fluid in interlobular septa), and finally bilateral alveolar opacities in a "bat-wing" or "butterfly" distribution. Cardiogenic edema also frequently shows bilateral pleural effusions and an enlarged cardiac silhouette. In non-cardiogenic edema (ARDS), the infiltrates tend to be more diffuse and peripheral without cardiomegaly or effusions.

BNP and NT-proBNP levels are critical for distinguishing cardiogenic from non-cardiogenic causes at the bedside. A BNP < 100 pg/mL essentially rules out heart failure as the cause. A BNP > 400 pg/mL makes cardiogenic edema highly likely. Values between 100 and 400 pg/mL fall in a gray zone and require clinical correlation. Be aware that renal failure elevates BNP regardless of cardiac function, and obesity lowers BNP (fat tissue clears natriuretic peptides), which can create falsely reassuring levels.

Echocardiography should be obtained to evaluate left ventricular systolic function (ejection fraction), diastolic filling patterns, and valvular pathology. This is especially important to identify treatable precipitants such as acute mitral regurgitation, aortic stenosis, or wall motion abnormalities suggesting acute MI.

The $A\text{-}aA\backslash text\{-\}a$ gradient is calculated as:

$$A\text{-}a\text{ gradient}=[Fi{O}_2\times (P_{atm}-P_{H_{2}O})-\frac{PaC{O}_2}{R}]-Pa{O}_{2}A\backslash text\{-\}a\backslash \; \backslash text\{gradient\}\; =\; \backslash left[FiO\_2\; \backslash times\; (P\_\{atm\}\; -\; P\_\{H\_2O\})\; -\; \backslash frac\{PaCO\_2\}\{R\}\backslash right]\; -\; PaO\_2$$

An elevated gradient confirms a parenchymal process (pulmonary edema, ARDS, PE) as opposed to hypoventilation, which has a normal gradient.

The Swan-Ganz catheter (right heart catheterization) remains the gold standard for differentiating cardiogenic from non-cardiogenic pulmonary edema. A pulmonary capillary wedge pressure (PCWP) greater than 18 mmHg confirms a cardiogenic etiology. However, this is an invasive test and is reserved for cases where the diagnosis remains unclear after non-invasive workup or when the patient is hemodynamically unstable and requires precise hemodynamic monitoring.

04Management and Treatment

Management Walkthrough

Acute cardiogenic pulmonary edema is a medical emergency. The first step is to sit the patient upright to reduce venous return and lower pulmonary capillary pressure. Supplemental oxygen should be provided immediately, and if the patient remains hypoxic or has significant respiratory distress, non-invasive positive pressure ventilation (CPAP at 5 to 10 cmH2O, or BiPAP) should be applied. CPAP/BiPAP works by increasing intrathoracic pressure, which reduces preload, lowers transmural left ventricular pressure (effectively reducing afterload), and recruits fluid-filled alveoli. Multiple trials have shown that early non-invasive ventilation reduces intubation rates and mortality.

IV furosemide is the cornerstone of pharmacologic management. Give 20 to 80 mg IV as a bolus (if the patient is already on chronic oral furosemide, the initial IV dose should be equal to or greater than their home dose). Furosemide has a biphasic mechanism: it causes venodilation within 5 minutes (reducing preload before diuresis even begins) and then produces diuresis at 20 to 30 minutes. If the response is inadequate after 20 minutes, the dose can be doubled. Monitor urine output closely; aim for at least 0.5 to 1 mL/kg/hour.

IV nitroglycerin is started at 5 to 10 mcg/min and titrated upward every 5 minutes. It primarily reduces preload through venodilation, and at higher doses, it also reduces afterload. It is contraindicated if the patient has taken phosphodiesterase-5 inhibitors (sildenafil, tadalafil) within 24 to 48 hours, or if systolic blood pressure is below 90 mmHg.

If the patient is hypotensive or in cardiogenic shock, diuretics and vasodilators are contraindicated. Instead, start dobutamine (a beta-1 agonist/inotrope) at 2 to 20 mcg/kg/min. If the patient is on chronic beta-blocker therapy, milrinone (a phosphodiesterase-3 inhibitor) is preferred because its mechanism bypasses the beta receptor. In refractory cardiogenic shock, consider mechanical circulatory support.

Long-term management of heart failure with reduced ejection fraction (HFrEF) follows the four-pillar regimen: ACE inhibitor or ARB (or ARNI), beta-blocker, aldosterone antagonist, and SGLT2 inhibitor. These are all started once the patient is clinically stable and euvolemic. Beta-blockers must never be started during an acute decompensation episode because they can worsen heart failure acutely. They are initiated or resumed only after the patient is stable and dry.

For non-cardiogenic pulmonary edema (ARDS), diuretics are generally not helpful because the edema is caused by permeability, not pressure. Management centers on lung-protective ventilation with low tidal volumes (6 mL/kg of ideal body weight, not actual body weight), keeping plateau pressure below 30 cmH2O, and applying appropriate PEEP. If the $Pa{O}_2\mathrm{/}Fi{O}_{2}PaO\_2/FiO\_2$ ratio remains below 150 despite optimization, prone positioning for at least 12 to 16 hours per day has a mortality benefit. The underlying cause (sepsis, aspiration, pancreatitis) must be treated concurrently.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on pulmonary edema questions is by failing to differentiate cardiogenic from non-cardiogenic edema. Both present with bilateral infiltrates and hypoxemia, and the vignette may not immediately make the distinction obvious. The critical pivot point is the BNP level and PCWP value. If BNP is normal and the clinical context includes a recent insult (sepsis, aspiration, trauma, pancreatitis, transfusion), think ARDS. If BNP is elevated and the patient has an S3 gallop, JVP elevation, or peripheral edema, think cardiogenic. When the vignette gives you a Swan-Ganz reading, a PCWP above 18 mmHg confirms cardiogenic etiology.

Another frequent trap involves "flash" pulmonary edema. A patient presents with sudden-onset severe dyspnea and bilateral pulmonary edema but has a preserved ejection fraction on echocardiography. Students often dismiss cardiogenic edema because the EF is normal. Flash pulmonary edema is classically triggered by acute hypertensive crisis, bilateral renal artery stenosis, or acute mitral regurgitation. The left ventricle may contract normally, but diastolic dysfunction or acute afterload mismatch causes the backup of pressure into the pulmonary vasculature. Always consider diastolic heart failure (HFpEF) and valvular emergencies when EF is preserved.

Students also stumble on management sequencing. In an acutely hypoxic and dyspneic patient, the next best step is non-invasive positive pressure ventilation and IV furosemide, not intubation (unless the patient is obtunded or in respiratory arrest). Starting beta-blockers during an acute decompensation episode is a classic wrong answer. And administering large volumes of IV fluids to a patient with bilateral pulmonary infiltrates before confirming that the edema is non-cardiogenic is a dangerous mistake that worsens cardiogenic edema.

Finally, remember that morphine, once considered a standard treatment for acute pulmonary edema, is now discouraged in current guidelines. Multiple studies have associated morphine use with increased intubation rates, ICU admissions, and mortality. If morphine appears as an answer choice alongside CPAP, furosemide, or nitroglycerin, it is almost certainly the wrong answer.

The core competency being tested in pulmonary edema questions is the ability to rapidly categorize the type of edema based on clinical and diagnostic clues, choose the correct initial management based on hemodynamic status (hypertensive vs. normotensive vs. hypotensive), and avoid outdated or harmful interventions.